CytomX Therapeutics, Inc. (CTMX) vs Oculis Holding AG (OCS)

CytomX Therapeutics, Inc. and Oculis Holding AG are both Biotechnology companies. CytomX Therapeutics, Inc. and Oculis Holding AG are of similar size ($599.2M and $579.5M). Oculis Holding AG grew revenue faster over the last twelve months: 65.8% against −87.0%. CytomX Therapeutics, Inc. has the higher net margin (−451.6% vs −6,870.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, CytomX Therapeutics, Inc. leads on 12 and Oculis Holding AG on 3.

Valuation

Metric CTMX OCS Biotechnology median
P/E n/m n/m 7.88
P/S 32.30 385.70 11.47
P/B 1.96 2.05 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 14.45 191.30 10.73
Earnings yield (18.52%) (18.77%) (28.84%)
Free cash flow yield (13.98%) (14.56%) (23.03%)

Profitability

Metric CTMX OCS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (476.19%) (7,383.66%) 0.00%
Net margin (451.62%) (6,870.05%) 0.00%
Free cash flow margin (450.27%) (5,525.64%) 0.00%
Return on equity (39.18%) (44.87%) (57.72%)
Return on assets (29.72%) (37.69%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CTMX OCS Biotechnology median
Revenue growth (TTM) (87.03%) 65.83% 5.64%
EPS growth (last fiscal year) (139.47%) 5.39% —
Revenue growth, 5-year CAGR (5.36%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CTMX OCS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 9.36 8.35 4.73
Net debt to EBITDA 5.91 2.60 0.96

Dividend

Metric CTMX OCS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric CTMX OCS Biotechnology median
Market cap 599.22m 579.54m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack